Biogen amends aducanumab deal terms, again

Shares of US biotech major Biogen (Nasdaq: BIIB) edged up 2% to $278.95 within an hour or so of the US biotech major announcing it had once again tweaked the terms of its deal with privately-held Swiss firm Neurimmune.

Biogen said it has exercised its option to further reduce the previously-negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase III investigational treatment for early Alzheimer’s disease.

Biogen will make a one-time $50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. The reduced royalty rates on potential commercial sales of aducanumab will be in the high single digits to low-teens.